Background. Determining if a kidney from a marginal donor is likely to elicit a strong and specific immune response, leading to an increased risk of acute rejection, is of importance in renal transplantation. Methods. In this study, we analysed the effect of extended criteria donor (ECD) on the incidence of biopsy-proven acute rejection (BPAR) and the effect of immunological risk factors on graft outcome in a large cohort of kidney transplant recipients (n = 2121 patients) grafted with ECD (n = 656 patients) or optimal donor (OD) (n = 1465 patients).
Introduction
The growing organ shortage represents a major challenge in organ transplantation. One strategy that has been used to increase the kidney donor pool is to include individuals who would have been deemed unsuitable according to 'marginal' or extended criteria donors (ECD) [1] [2] [3] [4] [5] . Before 2002, no universal or unequivocal definition of marginal transplantable kidney was available, and intuitively, most kidneys likely to display poor graft outcome were discarded [2] . Since 2002, to expand the existing donor selection criteria, Port et al. identified donor factors significantly associated with a poor graft outcome defined as ECD [6] . According to the United Network for Organ Sharing (UNOS) definition, ECD grafts are associated with reduced post-transplant function and worse allograft survival [6] . However, many pre-, peri-and post-transplantation factors are likely to contribute to the poor graft performance observed in recipients of ECD transplants [2] . An impaired ability to repair the tissue can lead to sensitivity to a prolonged cold ischaemia time, thus increasing the risk of a delayed graft function [2, [7] [8] [9] [10] [11] . Pre-transplant histological lesions also sensitize renal allografts to nephrotoxic drugs, especially calcineurin inhibitors (CNI) [12, 13] . Immunological determinants may also affect graft performance; however, the conclusions drawn from the previous experimental and clinical findings have been inconsistent.
In the first clinical study by de Fijter et al., a multivariate analysis revealed an increased cumulative incidence of acute rejection (AR) episodes in patients receiving a graft from donors more than 50 years old [14] . Consistent with these findings, Reutzel-Selke et al. showed an increased immunogenicity of kidney grafts from older donor animals in an experimental kidney transplantation model [15] . Finally, in a prospective age-matching analysis of the Eurotransplant Senior Program, allocation of kidneys from donors aged ≥65 years to recipients ≥65 years led to a rejection rate of 10% higher than in controls (any graft transplanted into an elderly recipient) [16] . Together, these studies suggest that grafts from older donors elicit a stronger immune response than grafts from younger donors in the early period after transplantation. This is likely to be related to immunosenescence and functional changes that occur with increasing age. These changes act synergistically to stimulate a non-specific inflammation and immune recognition, mediated by the upregulation of pro-inflammatory cytokines, major histocompatibility complex (MHC) antigens and the activation of antigen-presenting cells (APC) [17, 18] . In contrast, a recent study has shown that, although kidneys from old donors exhibit higher levels of senescence markers than those from younger donors, they are not more immunogenic [19] . Moreover, it has also been clearly demonstrated that ageing impairs an adaptive T-cell function [20, 21] .
Determining whether kidneys from marginal or elderly donors are likely to elicit a strong and specific immune response and thus confer an increased risk of acute rejection is of great importance for both kidney allocation and choice of immunosuppressive regimen. This could have implications for the choice of the appropriate recipient for a marginal donor transplant. Indeed, determining the potential effects of the recipient's immunological risk on the outcome of transplantation may thus shed light on the suitability of the 'old for old'strategy during the kidney allocation process.
Here, we analysed in a large cohort of recipients (n = 2121 patients) of kidney transplants from deceased ECD (n = 656 patients) or optimal donors (OD) (n = 1465 patients) the influence of ECD on the incidence of biopsy-proven acute rejection (BPAR). We also investigated the effect of immunological risk factors on ECD graft outcome.
Materials and methods
We retrospectively studied all recipients of deceased donor kidney transplants from six renal transplant centres from the French region of Ile de France listed in the Agence de la Biomedecine (ABM) database between January 1998 and December 2004. All patients included in this database gave informed consent to participate to clinical data collection after renal transplantation. Living donor, multiple organ and paediatric transplants (<16 years) were excluded, giving a total of 2121 grafts for analysis. Donor and recipient characteristics must be listed in the national information system. A routine yearly follow-up, graft failure and patient death must be reported to the ABM registry. Demographic, medical, follow-up and donor procurement data are also recorded. We analysed the following data: gender and age of recipients and donors, the recipient mean duration of dialysis prior to transplantation, the number of human leucocyte antigen (HLA) mismatches, the number of previous renal grafts and panel-reactive antibody (PRA) level for the recipient, pre-harvesting serum creatinine level, donor history of hypertension, donor episodes of cardiac resuscitation or prolonged hypotension, the cold ischaemia time, immunosuppressive regimen, the year of transplantation, incidence of delayed graft function (DGF), defined as the need for dialysis in the first 7 days after renal transplantation, and graft and recipient survival. Recipient immunological risk factors were defined as one or more previous grafts and/ or PRA level >20%. The BPAR rate was obtained from histopathology data and included all patients with at least one episode of AR during the entire study period confirmed by biopsy using the Banff 97 allograft classification criteria [22] . The borderline acute rejection was excluded from the analysis. No protocol biopsies were included in this study. Treatment of BPAR mostly consisted of a pulse of intravenous methylprednisolone on three consecutive days and anti-thymoglobulin (ATG) in cases of steroid-resistant rejection. ECD was defined using the UNOS criteria: all donors aged 60 years and over, and donors aged 50-59 years with at least two additional risk factors, including cerebrovascular accident as a cause of death, previous history of hypertension and serum creatinine levels >1.5 mg/dl prior to transplantation [6] . Donors from transplant patients included in this study between 1998 and 2002 were not defined as ECD at the time of transplant. This definition was used retrospectively, based on the UNOS criteria. 
Statistical analysis
All continuous variables were expressed as mean ± 1 standard deviation or as median with 1st and 3rd quartiles [interquartile range (IQR)], depending on the distribution of the variable; all categorical variables were expressed as n and percentage of total. Patient characteristics were compared between groups using a t-test for continuous variables and a χ 2 test for categorical variables. We used a Mantel-Haenszel test when adjusting for a third variable. A logistic regression model was used to test the association between BPAR and ECD/OD kidney transplants, when adjusting on potential confounding factors. The model estimated the adjusted odds ratios (OR) with their 95% confidence intervals (CI). For graft survival analysis, we considered the return to dialysis as the end point and reported graft survival with death as censored data. Graft survival was estimated using the Kaplan-Meier method and compared for the different categories using a log-rank test. The confounding factors were studied two by two (2 2 ) with an adjusted log-rank test. A P-value < 0.05 was considered statistically significant.
Results

Population characteristics in the ECD and control groups
We recorded demographic, clinical and biological data from 2121 transplant recipients (Table 1) . Patients were divided into two groups: those fulfilling (ECD group) or not fulfilling (OD group) the ECD criteria. The data from 656 patients (30.9%) (425 men and 231 women) receiving an ECD kidney graft were compared to the data from 1465 patients of the OD group (870 men and 595 women). The mean follow-up time after transplantation was 48.5 ± 26.6 months in the OD transplant group and 41.3 ± 25.3 months in the ECD group (P < 0.001).
Among the 656 ECD transplant recipients, 475 (72.4%) had received kidneys from donors older than 60 years and 181 (27.6%) from donors aged between 50 and 59 years, displaying at least two additional risk factors.
Consistent with the ECD criteria, donor age was higher in the ECD group (63.1 ± 6.9 years and 40.8 ± 12.2 years in the ECD and OD groups, respectively, P < 0.001). Mean recipient age was also significantly higher in the ECD group than in the OD group (52.9 ± 11.2 years and 44.6 ± 11.5 years, respectively, P < 0.001). The proportion of patients with a previous history of kidney transplantation significantly differed between the two groups (9.7% in the ECD group and 15.3% in the OD group, P < 0.001). A PRA percentage of >20% was more frequent in the OD group (15.8% in the OD group and 11.6% in the ECD group, P = 0.01). Thus, the recipient immunological risk factors, defined as previous graft history and/or PRA percentage of >20%, were more frequent in the OD group than in the ECD group (23.0% and 16.2%, respectively, P = 0.008). Moreover, the incidence of DGF was significantly higher in the ECD group than in the OD group (39.5% and 19.3%, respectively, P = 0.002).
Incidence of BPAR
BPAR occurred in 356 of the 2121 (16.8%) kidney transplant recipients. The incidence of BPAR did not statistically differ between recipients receiving ECD transplants (105/656, 16%) and those receiving OD transplants (251/ 1465, 17%) (P = 0.52) (Figure 1) . These values remained similar for the two groups taking into account the recipient age (recipient <40 years, recipient between 40 and 59 years, and ≥60 years) (Figure 1 ). Thus, BPAR was Immunological risk in recipients of ECD renal allograft 2747
15.1% and 19.1% for recipients <40 years (P = 0.37); 17.1% and 16.9% for recipients aged from 40 to 59 years (P = 0.95); and 14.4% and 10.9% (P = 0.36) for recipients aged ≥60 years, in the ECD and OD groups, respectively. However, the incidence of acute rejection episodes significantly decreased with ageing in patients from the OD group (P = 0.034) contrasting with the ECD group (P = 0.68). The BPAR rate also remained similar between the ECD and OD groups after adjustment for immunological risk, including the previous transplantation history and PRA level (recipients with immunological risk: 17.9% and 17.5% in ECD and OD groups, respectively, P = 0.92; without immunological risk: 15.6% and 17% in the ECD and OD groups, respectively, P = 0.47). Moreover, the donor age under or over 50 years was not a predictive factor for BPAR in a univariate analysis (16.4% when the donor age was ≥50 years, and 17.1% when the donor age was <50 years, P = 0.64).
In a multivariate analysis, taking into account recipient age, donor age, donor resuscitation, previous transplant, PRA levels, HLA mismatches, immunosuppression protocols [including use of mycophenolate mofetil (MMF)], cold ischaemia time, incidence of DGF and year of transplantation (before and after 2002), we showed that the difference in incidence of BPAR between the two groups of patients grafted with ECD or OD remains statistically non-significant (in ECD group: OR = 0.955; 95% CI 0.673-1.354; P = 0.78) ( Table 2) .
Kaplan-Meier analysis of graft survival
We first analysed the death-censored graft survival in the two groups of patients. As previously demonstrated [6] , graft survival at 1, 2 and 5 years was significantly lower in the ECD group than in the OD group (P = 0.013). Graft survival was 92.9 ± 1.1% and 94.7 ± 0.6% at 1 year, 91 ± 1.1% and 93.1 ± 1.1% at 2 years, and 82.9 ± 1.9% and 86.7 ± 1.0% at 5 years for recipients of ECD and OD transplants, respectively (Figure 2) .
We next analysed the death-censored graft survival data for the OD and ECD groups, as a function of immunological status and recipient age (Figures 3 and 4) . For recipients without immunological risk, graft survival in the ECD group was significantly lower than in the OD group (P < 0.001). In contrast, for recipients with immunological risk, graft survival rates were similar for the two groups (P = 0.64), suggesting that immunological risk was not an additional risk factor for graft failure in the ECD group recipients. Interestingly, OD graft survival in the lowimmunological risk recipients was significantly higher than in the high-immunological risk recipients (P = 0.011). In contrast, we did not find any statistical difference in graft survival between ECD recipients with or without immunological status (P = 0.46). For recipients under 40 years old or between 40 and 59 years, graft survival was significantly lower for the ECD group than for the OD group (P = 0.026 and P = 0.001, respectively). In recipients aged 60 years and older, the graft survival rate was similar for the two groups (P = 0.28). These results strongly suggest that age p = 0.013 less than 59 could be a risk factor for a poor graft survival in recipients of ECD transplants. Moreover, we found that graft survival in OD recipients <40 years old was lower than in OD recipients >40 years (P < 0.0001). We did not find a significant difference in graft survival for ECD recipients of the different age groups (P = 0.17). Fig. 4 . Effect of recipient age on the death-censored graft survival in the OD and ECD groups (Kaplan-Meier curves). Statistically significant differences were found for recipients under 40 years of age (P = 0.026) (A) and for recipients between 40 and 59 years (P = 0.001) (B), but not for recipients aged 60 or over (P = 0.28) (C).
Discussion
We analysed the immunogenicity of ECD transplants by studying the incidence of acute rejection and the impact of immunological factors on graft survival in a large patient cohort. In contrast with previous studies, the incidence of BPAR was not higher in recipients of transplants from ECD or donors aged ≥50 years than in recipients of transplants from OD or donors aged <50 years. This was independent of other immunological risk factors. These results are strengthened by the higher incidence of DGF observed in the ECD group, a potent risk factor for acute rejection [23] , although it is not an independent risk factor in our study. Moreover, although graft survival was markedly reduced in recipients of transplants from ECD or donors aged ≥50 years, graft outcome was not significantly affected by immunological factors. Our results have to be moderated for several reasons: Firstly, since our study did not include protocol biopsies, immunological damage induced by subclinical cellular or humoral rejection cannot be excluded. Next, some variables that are likely to influence the incidence of BPAR were not quite homogeneously distributed in both groups: these factors included mean number of HLA mismatches, use of MMF, donor cardiac resuscitation, cold ischaemia time and incidence of DGF. We performed a multivariate analysis taking into account all factors that could positively or negatively influence immunological risk, and the incidence of BPAR remains not statistically different between the two groups. These results are in agreement with two recent studies [24, 25] but are in contrast with other clinical trials [14, 16] . These apparently contradictory results may have some explanations. Firstly, in our study, incidence of BPAR was defined as at least one episode of AR occurring in all patients during the entire study period, whereas de Fijter et al. analysed cumulative incidence of acute rejection episodes. Next, in a study by Frei et al., AR rate was compared between Eurotransplant Senior Program groups including donor and recipient age more than 65 years and 'any to old' groups defined as recipient age between 60 and 64 years old independently of donor age. Recent experimental data published by Melk et al. are likely to account for these apparently conflicting results [19] . The authors found that kidney allografts from old mice display an increased parenchymal susceptibility to transplant stress and high levels of the senescence marker p 16INK4a ; however, the alloimmune response including T-cell infiltrate, levels of cytotoxic markers and MHC were not higher than those in recipients of transplants from young donor mice. These findings clearly demonstrate that the recipients of old donor kidneys exhibit an increased susceptibility to peri-and posttransplant damage, potentially resulting in acute rejection, but that differences in recipient's immune response to the greater immunogenicity of organs from old donors have no additional effect on graft outcome. The authors suggested that the differences observed in the previous data [14] could be related to the fact that tubulitis is a late stage of epithelial deterioration, in which lymphocytes can no longer be eliminated.
We did not observe any significant effects of recipient age on the incidence of acute rejection after transplantation with kidneys from ECD or donors aged ≥50 years. In a study by de Fijter et al., the risk of AR was found to be Age of recipient >60 years p = 0.28
Immunological risk in recipients of ECD renal allograft 2751 significantly increased in recipients aged <50 years [14] . This recent finding is consistent with the previous experimental data showing that ageing is associated with a reduced cellular immunity and CD4+ T-cell response and a reduced ability to reject the skin allograft [21, 26] . However, immune senescence is likely to be affected by the accumulation of memory T cells observed in aged recipients who often have an alloimmune response to transplantation [27] . This paradox may be explained by recent data showing that aged mice are able to reject a skin allograft at a similar rate to that observed for young transplant recipients, independently of donor age, but display an interleukin (IL)-17-mediated response mediated by memory CD4+ cells rather than a classical interferon (IFN)-response [28] . Thus, ageing seems to cause more qualitative rather than quantitative changes in the alloimmune response. Our analysis of factors determining graft survival revealed an effect of classical factors including cold ischaemia time (CIT) and number of previous grafts (data not shown), but also showed an effect of recipient age <40 years. The effect of recipient age on ECD graft survival has been previously reported [29, 30] . In this recent report, the authors showed that, although renal transplantation from older donors to older recipients did not improve overall graft survival, worse results were obtained when grafts from older donors were used in young recipients. A discrepancy in the metabolic demand between donor and recipient and a high sensitivity to chronic hyperfiltration in allografts, with a reduced number of functioning nephrons, may in part account for these results, although we cannot eliminate the influence of immunological determinants, such as an increase immune response in younger recipients.
Factors that are likely to influence graft from ECD outcome may be related to immunological and non-immunological determinants. Although it might be difficult to assess respective influence of each factors, our multivariate analysis rather support the hypothesis that the non-immunological factors play a determinant role and could mainly be intrinsic to the donor and related to a reduced capacity of 'marginal' tissues to repair pre-, peri-and post-transplant damage such as ischaemia-reperfusion damage, acute rejection and renal toxicity of anti-calcineurin agents.
Our findings suggest that the host immune response does not to play a key role in graft outcome. Allocation of ECD organs in clinical practice remains problematic. Given that graft survival is reduced in older recipients, graft survival may be optimized by the preferential transplantation of ECD into older recipients. This notion underlies the allocation system developed by the Eurotransplant Senior Program, whereby allocation is based on matching the metabolic demand of the graft recipient to the excretory capacity of the donor organ [31] . Our study does not suggest that the rationale of this project should be modified for recipient immunological risk, nor does it justify the requirement of a specific immunosuppressive regimen or immune monitoring.
Introduction
Children with intellectual disability (ID) have a higher mortality compared with the general population [1] . Genetic syndromes and chromosome aberrations are the main causes of ID, and in some cases, congenital anomalies of the urinary tract and chronic kidney disease (CKD) are associated [2] . While renal transplantation is regarded as the treatment of choice for CKD [3, 4] , its use in patients with ID is less frequent with most patients being treated with dialysis [5] . Renal transplantation in these patients raises a number of questions related not only to outcome but also with regard to the ethics of diverting scarce resources and donor kidneys away from patients with normal mental ability [6, 7] . Ohta et al. and Baqi et al. observed that the outcome of kidney transplantation in patients with ID is acceptable [6, 8] . In this paper, we report our results of renal transplantation in patients with ID over a 5-year period.
